

MEDICAL ASSISTANCE BULLETIN

ISSUE DATE

March 25, 2022

EFFECTIVE DATE

March 25, 2022

NUMBER

01-22-07, 08-22-07, 09-22-06, 10-22-02 28-22-01, 31-22-07, 33-22-05

SUBJECT

Additions to the Medical Assistance Program Fee Schedule for Multiple Respiratory Pathogens Laboratory Tests BY

Sally A. Kozak,
Deputy Secretary

Sally a. Kozal

Office of Medical Assistance Programs

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx.

PURPOSE:

The purpose of this bulletin is to announce the addition of two procedure codes, 87636 and 87637, to the Medical Assistance (MA) Program Fee Schedule for use in laboratory testing for multiple respiratory pathogens, including SARS-CoV-2 (COVID-19).

SCOPE:

This bulletin applies to MA enrolled providers who render laboratory testing for MA beneficiaries in the fee-for-service delivery system. Providers rendering services in the managed care delivery systems are to address any billing and payment questions with the applicable managed care organization.

BACKGROUND/DISCUSSION:

On October 7, 2020, the American Medical Association <u>announced</u> the addition of two newly approved procedure codes to the Current Procedural Terminology code set, procedure codes 87636 and 8763, to report nucleic acid assays that allow a single test to simultaneously detect the novel coronavirus and a combination of common viral infectious agents, including influenza A/B and respiratory syncytial virus (RSV). Procedure code 87636 is to be used to report combined respiratory virus multiplex testing for COVID-19 with influenza A and influenza B. Procedure code 87637 is to be used for COVID-19 with influenza A, influenza B, and RSV.

On April 26, 2021, the Centers for Medicare & Medicaid Services (CMS) announced

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

Fee-for-service provider service center: 1-800-537-8862

Visit the Office of Medical Assistance Programs website at:

 $\frac{https://www.dhs.pa.gov/providers/Pages/Health\%20Care\%20for\%20Providers/Contact-Information-for-Providers.aspx.}{$

that Medicare will permit the use of procedure code 87636 with the QW modifier for claims submitted by a facility with a valid, current Clinical Laboratory Improvement Amendments (CLIA) certificate of waiver. On June 11, 2021, CMS <u>announced</u> that Medicare will permit the use of procedure code 87637 with the QW modifier for claims submitted by a facility with a valid, current CLIA certificate of waiver.

PROCEDURE:

The Department is adding laboratory test procedure codes 87636 and 87637 to the MA Program Fee Schedule as follows, effective with dates of service on and after March 21, 2022. Claims for tests that are performed in facilities having a valid, current CLIA certificate of waiver must include the QW modifier.

Procedure Code	Procedure Code Description	Provider Type/ Specialty	Place of Service/ Modifier	MA Fee	Limits	Prior Authorization Required
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	01/016 01/016 01/017 01/017 01/183 01/183 08/082 08/082 09/AII 09/AII 10/100 10/100 28/280 28/280 31/AII 31/AII 33/335 33/335	23 23/QW 23 23/QW 22 22/QW 49 49/QW 11 11/QW 11 11/QW 11 11/QW 11 11/QW	\$112.86 per test	1 test per day	No
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus,	01/016 01/016 01/017 01/017 01/183 01/183 08/082 08/082 09/AII 09/AII 10/100	23 23/QW 23 23/QW 22 22/QW 49 49/QW 11 11/QW	\$112.86 per test	1 test per day	No

multiplex amplified	10/100	11/QW		
probe technique	28/280	81		
	28/280	81/QW		
	31/All	11		
	31/All	11/QW		
	33/335	11		
	33/335	11/QW		

Providers may access the online version of the MA Program Fee Schedule, which reflects these changes, on the Department's website at: https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx

Additional information and guidance pertaining to COVID-19 testing can be found at the following links:

- American Medical Association <u>https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance</u>
- Centers for Disease Control and Prevention <u>https://www.cdc.gov/coronavirus/2019-ncov/lab/point-of-care-testing.html</u>
- Pennsylvania Department of Health https://www.health.pa.gov/topics/disease/coronavirus/Pages/Coronavirus.aspx

ATTACHMENT:

"Procedure Code Additions to the Medical Assistance Program Fee Schedule for Multiple Respiratory Pathogens Laboratory Tests"

Procedure Code Additions to the Medical Assistance Program Fee Schedule for Multiple Respiratory Pathogens Laboratory Tests

Procedure Code	Description	Provider Type	Provider Specialty	Place of Service	Info Modifier	Effective Date	MA Fee	Prior Auth	MA units	Limits
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	01	016, 017	23		March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	01	016, 017	23	QW	March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	01	183	22		March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	01	183	22	QW	March 21, 2022	\$112.86	No	per test	once per day

1	1		1	•	1	ı	1 1		1	
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	08	082	49		March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	08	082	49	QW	March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	09	All	11		March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	09	All	11	QW	March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	10	100	11		March 21, 2022	\$112.86	No	per test	once per day

			-	i		•	•	1		
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	10	100	11	QW	March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	28	280	81		March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	28	280	81	QW	March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	31	AII	11		March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	31	AII	11	QW	March 21, 2022	\$112.86	No	per test	once per day

87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	33	335	11		March 21, 2022	\$112.86	No	per test	once per day
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	33	335	11	QW	March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	01	016, 017	23		March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	01	016, 017	23	QW	March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	01	183	22		March 21, 2022	\$112.86	No	per test	once per day

87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	01	183	22	QW	March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	08	082	49		March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	08	082	49	QW	March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	09	All	11		March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	09	All	11	QW	March 21, 2022	\$112.86	No	per test	once per day

87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	10	100	11		March 21, 2022	\$112.86	No	pertest	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	10	100	11	QW	March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	28	280	81		March 21, 2022	\$112.86	No	per test	once per
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	28	280	81	QW	March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	31	All	11		March 21, 2022	\$112.86	No	per test	once per day

87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	31	All	11	QW	March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	33	335	11		March 21, 2022	\$112.86	No	per test	once per day
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	33	335	11	QW	March 21, 2022	\$112.86	No	per test	once per day